On August 10, 2022, the Food and Drug Administration (FDA) granted regular approval to capmatinib (brand name: Tabrecta) for the treatment of metastatic non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping mutation. Here, MET is linked to non-small cell lung carcinoma.